Novel point mutation (W184R) in neonatal type 2 Gaucher disease
Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identifie...
Gespeichert in:
Veröffentlicht in: | Pediatric and developmental pathology 2000-03, Vol.3 (2), p.180-183 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 183 |
---|---|
container_issue | 2 |
container_start_page | 180 |
container_title | Pediatric and developmental pathology |
container_volume | 3 |
creator | Choy, F Y Wong, K Vallance, H D Baldwin, V |
description | Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identified a novel mutation in a patient of Russian-British descent who died of type 2 Gaucher disease a few hours after birth. A heterozygous T --> C transition mutation in exon 6, cDNA nucleotide position 667, results in the substitution of tryptophan by arginine at amino acid residue 184 (W184R) of glucocerebrosidase. This mutation creates a new cleavage site for the restriction endonuclease Hinf1. We developed a method that utilizes Hinf1 restriction endonuclease analysis to confirm the presence of the mutation and test family members. The second mutation identified in the other glucocerebrosidase allele of the patient is mutation L444P, a severe mutation frequent in type 2 and 3 Gaucher disease. Since the patient died very shortly after birth, we postulate that the W184R/L444P genotype may result in little or no detectable glucocerebrosidase activity and thus a poor prognosis. |
doi_str_mv | 10.1007/s100249910018 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70908605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70908605</sourcerecordid><originalsourceid>FETCH-LOGICAL-p122t-7858f4295909f84c901570609525a4af26b6a36bb41809304d96d32d69a15f5c3</originalsourceid><addsrcrecordid>eNo1j01LxDAYhHNQ3HX16FVyEj1U33wnJ5FFV2FREMVjedumGOmXTSrsv7fgepmB4WGYIeSMwTUDMDdxVi6dm43ZA7Jk4ESmuNYLchzj15wao-GILBho40DYJbl97n98Q4c-dIm2U8IU-o5efjArX69o6Gjn-w4TNjTtBk853eBUfvqRViF6jP6EHNbYRH-69xV5f7h_Wz9m25fN0_pumw2M85QZq2wtuVMOXG1l6YApAxqc4gol1lwXGoUuCsnsPBpk5XQleKUdMlWrUqzIxV_vMPbfk48pb0MsfdPgPHCKuQEHVoOawfM9OBWtr_JhDC2Ou_z_svgFQz9SjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70908605</pqid></control><display><type>article</type><title>Novel point mutation (W184R) in neonatal type 2 Gaucher disease</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><source>Alma/SFX Local Collection</source><creator>Choy, F Y ; Wong, K ; Vallance, H D ; Baldwin, V</creator><creatorcontrib>Choy, F Y ; Wong, K ; Vallance, H D ; Baldwin, V</creatorcontrib><description>Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identified a novel mutation in a patient of Russian-British descent who died of type 2 Gaucher disease a few hours after birth. A heterozygous T --> C transition mutation in exon 6, cDNA nucleotide position 667, results in the substitution of tryptophan by arginine at amino acid residue 184 (W184R) of glucocerebrosidase. This mutation creates a new cleavage site for the restriction endonuclease Hinf1. We developed a method that utilizes Hinf1 restriction endonuclease analysis to confirm the presence of the mutation and test family members. The second mutation identified in the other glucocerebrosidase allele of the patient is mutation L444P, a severe mutation frequent in type 2 and 3 Gaucher disease. Since the patient died very shortly after birth, we postulate that the W184R/L444P genotype may result in little or no detectable glucocerebrosidase activity and thus a poor prognosis.</description><identifier>ISSN: 1093-5266</identifier><identifier>DOI: 10.1007/s100249910018</identifier><identifier>PMID: 10679038</identifier><language>eng</language><publisher>United States</publisher><subject>Base Sequence ; DNA - analysis ; DNA Primers - chemistry ; DNA Restriction Enzymes - metabolism ; Fatal Outcome ; Gaucher Disease - enzymology ; Gaucher Disease - genetics ; Gaucher Disease - pathology ; Glucosylceramidase - genetics ; Humans ; Infant, Newborn ; Molecular Sequence Data ; Point Mutation ; Polymerase Chain Reaction ; Polymorphism, Restriction Fragment Length ; Restriction Mapping - methods</subject><ispartof>Pediatric and developmental pathology, 2000-03, Vol.3 (2), p.180-183</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10679038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choy, F Y</creatorcontrib><creatorcontrib>Wong, K</creatorcontrib><creatorcontrib>Vallance, H D</creatorcontrib><creatorcontrib>Baldwin, V</creatorcontrib><title>Novel point mutation (W184R) in neonatal type 2 Gaucher disease</title><title>Pediatric and developmental pathology</title><addtitle>Pediatr Dev Pathol</addtitle><description>Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identified a novel mutation in a patient of Russian-British descent who died of type 2 Gaucher disease a few hours after birth. A heterozygous T --> C transition mutation in exon 6, cDNA nucleotide position 667, results in the substitution of tryptophan by arginine at amino acid residue 184 (W184R) of glucocerebrosidase. This mutation creates a new cleavage site for the restriction endonuclease Hinf1. We developed a method that utilizes Hinf1 restriction endonuclease analysis to confirm the presence of the mutation and test family members. The second mutation identified in the other glucocerebrosidase allele of the patient is mutation L444P, a severe mutation frequent in type 2 and 3 Gaucher disease. Since the patient died very shortly after birth, we postulate that the W184R/L444P genotype may result in little or no detectable glucocerebrosidase activity and thus a poor prognosis.</description><subject>Base Sequence</subject><subject>DNA - analysis</subject><subject>DNA Primers - chemistry</subject><subject>DNA Restriction Enzymes - metabolism</subject><subject>Fatal Outcome</subject><subject>Gaucher Disease - enzymology</subject><subject>Gaucher Disease - genetics</subject><subject>Gaucher Disease - pathology</subject><subject>Glucosylceramidase - genetics</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Molecular Sequence Data</subject><subject>Point Mutation</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism, Restriction Fragment Length</subject><subject>Restriction Mapping - methods</subject><issn>1093-5266</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LxDAYhHNQ3HX16FVyEj1U33wnJ5FFV2FREMVjedumGOmXTSrsv7fgepmB4WGYIeSMwTUDMDdxVi6dm43ZA7Jk4ESmuNYLchzj15wao-GILBho40DYJbl97n98Q4c-dIm2U8IU-o5efjArX69o6Gjn-w4TNjTtBk853eBUfvqRViF6jP6EHNbYRH-69xV5f7h_Wz9m25fN0_pumw2M85QZq2wtuVMOXG1l6YApAxqc4gol1lwXGoUuCsnsPBpk5XQleKUdMlWrUqzIxV_vMPbfk48pb0MsfdPgPHCKuQEHVoOawfM9OBWtr_JhDC2Ou_z_svgFQz9SjQ</recordid><startdate>200003</startdate><enddate>200003</enddate><creator>Choy, F Y</creator><creator>Wong, K</creator><creator>Vallance, H D</creator><creator>Baldwin, V</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200003</creationdate><title>Novel point mutation (W184R) in neonatal type 2 Gaucher disease</title><author>Choy, F Y ; Wong, K ; Vallance, H D ; Baldwin, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p122t-7858f4295909f84c901570609525a4af26b6a36bb41809304d96d32d69a15f5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Base Sequence</topic><topic>DNA - analysis</topic><topic>DNA Primers - chemistry</topic><topic>DNA Restriction Enzymes - metabolism</topic><topic>Fatal Outcome</topic><topic>Gaucher Disease - enzymology</topic><topic>Gaucher Disease - genetics</topic><topic>Gaucher Disease - pathology</topic><topic>Glucosylceramidase - genetics</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Molecular Sequence Data</topic><topic>Point Mutation</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism, Restriction Fragment Length</topic><topic>Restriction Mapping - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choy, F Y</creatorcontrib><creatorcontrib>Wong, K</creatorcontrib><creatorcontrib>Vallance, H D</creatorcontrib><creatorcontrib>Baldwin, V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric and developmental pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choy, F Y</au><au>Wong, K</au><au>Vallance, H D</au><au>Baldwin, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel point mutation (W184R) in neonatal type 2 Gaucher disease</atitle><jtitle>Pediatric and developmental pathology</jtitle><addtitle>Pediatr Dev Pathol</addtitle><date>2000-03</date><risdate>2000</risdate><volume>3</volume><issue>2</issue><spage>180</spage><epage>183</epage><pages>180-183</pages><issn>1093-5266</issn><abstract>Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identified a novel mutation in a patient of Russian-British descent who died of type 2 Gaucher disease a few hours after birth. A heterozygous T --> C transition mutation in exon 6, cDNA nucleotide position 667, results in the substitution of tryptophan by arginine at amino acid residue 184 (W184R) of glucocerebrosidase. This mutation creates a new cleavage site for the restriction endonuclease Hinf1. We developed a method that utilizes Hinf1 restriction endonuclease analysis to confirm the presence of the mutation and test family members. The second mutation identified in the other glucocerebrosidase allele of the patient is mutation L444P, a severe mutation frequent in type 2 and 3 Gaucher disease. Since the patient died very shortly after birth, we postulate that the W184R/L444P genotype may result in little or no detectable glucocerebrosidase activity and thus a poor prognosis.</abstract><cop>United States</cop><pmid>10679038</pmid><doi>10.1007/s100249910018</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1093-5266 |
ispartof | Pediatric and developmental pathology, 2000-03, Vol.3 (2), p.180-183 |
issn | 1093-5266 |
language | eng |
recordid | cdi_proquest_miscellaneous_70908605 |
source | MEDLINE; SAGE Complete A-Z List; Alma/SFX Local Collection |
subjects | Base Sequence DNA - analysis DNA Primers - chemistry DNA Restriction Enzymes - metabolism Fatal Outcome Gaucher Disease - enzymology Gaucher Disease - genetics Gaucher Disease - pathology Glucosylceramidase - genetics Humans Infant, Newborn Molecular Sequence Data Point Mutation Polymerase Chain Reaction Polymorphism, Restriction Fragment Length Restriction Mapping - methods |
title | Novel point mutation (W184R) in neonatal type 2 Gaucher disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T19%3A44%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20point%20mutation%20(W184R)%20in%20neonatal%20type%202%20Gaucher%20disease&rft.jtitle=Pediatric%20and%20developmental%20pathology&rft.au=Choy,%20F%20Y&rft.date=2000-03&rft.volume=3&rft.issue=2&rft.spage=180&rft.epage=183&rft.pages=180-183&rft.issn=1093-5266&rft_id=info:doi/10.1007/s100249910018&rft_dat=%3Cproquest_pubme%3E70908605%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70908605&rft_id=info:pmid/10679038&rfr_iscdi=true |